What is CPVT?
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare, inherited channelopathy that typically manifests during childhood or adolescence (the first or second decade of life). It is caused by genetic mutations (primarily in the RYR2 gene) that regulate calcium handling within cardiomyocytes. This intracellular ionic imbalance renders the myocardium highly susceptible to severe, potentially fatal ventricular arrhythmias. These arrhythmic episodes are triggered by the surge of catecholamines (epinephrine) induced not only by physical exertion, but also by intense emotional stress (such as fear, anger, or anxiety) and sudden auditory stimuli.
Note: CPVT frequently presents as syncopal episodes accompanied by seizure-like activity; consequently, many pediatric patients are initially misdiagnosed with epilepsy.
Diagnosis
Because the baseline resting electrocardiogram (ECG) and transthoracic echocardiogram of these patients are entirely unremarkable, diagnosis relies heavily on:
- The documentation of characteristic bidirectional or polymorphic ventricular arrhythmias during an exercise stress test (or via ambulatory Holter monitoring).
- Genetic testing to identify pathogenic mutations, which is now considered mandatory to facilitate cascade screening of immediate family members.
Treatment
- Lifestyle Modifications: Strict disqualification from competitive sports and strenuous physical exertion remains mandatory.
- Pharmacotherapy: The first line of defense consists of beta-blockers (ideally nadolol, where available). In patients who experience breakthrough arrhythmias despite beta-blocker therapy, flecainide—which directly targets cardiac sodium and calcium channels—is added to the regimen.
- Left Cardiac Sympathetic Denervation (LCSD): Surgical sympathetic denervation is increasingly utilized, yielding excellent efficacy in mitigating the arrhythmogenic effects of epinephrine on the myocardium.
- Implantable Cardioverter-Defibrillator (ICD): Based on contemporary clinical data, ICD implantation is approached with extreme caution. The painful electrical shock delivered by an ICD can provoke a secondary, massive catecholamine surge, potentially triggering an unmanageable and fatal "arrhythmic storm". Consequently, ICD placement is strictly restricted as a last resort for patients who have sustained a cardiac arrest despite maximal tolerated pharmacotherapy and surgical denervation.